Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-25-00481 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Adrian Minson und 25 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, Australia. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Improved outcomes are needed for patients with high-risk (HR) large B-cell lymphoma (LBCL) who have 94%. Cytokine release syndrome was observed in 21% of patients, all ≤grade 2 and manageable. Overall and complete response rates were 100% and 98%, respectively. At 20.7-month median follow-up, the estimated 2-year progression-free survival and overall survival were 86% and 92%, respectively. CONCLUSION The combination of glofitamab with R-CHOP or Pola-R-CHP is deliverable and results in high rates of durable response in this population of younger patients with high-burden, HR LBCL, supporting its ongoing exploration as a 1L treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Peter MacCallum Cancer Centre, Melbourne, Australia.
- Royal Melbourne Hospital, Melbourne, Australia.
- University of Melbourne, Melbourne, Australia.
- Concord Repatriation Hospital, Sydney, Australia.
- Royal Adelaide Hospital, Adelaide, Australia.
- Royal Brisbane & Women's Hospital, Brisbane, Australia.
ORCID-Profile: Adrian Minson, Emma Verner, Wojt Janowski, Chan Y Cheah, Sumita Ratnasingam, Matthew Ku, Nada Hamad, Costas K Yannakou, Fiona Swain, Paul Neeson, Thiago M Steiner, Sally M Hunter, Rory Bennett, Jing Xie, John F Seymour, Michael J Dickinson
Zitieren
APA
Minson, A., Verner, E., Giri, P., Butler, J., Janowski, W., Cheah, C. Y., Ratnasingam, S., Wong, S. M., Ku, M., Hertzberg, M., Herbert, K., Hamad, N., Yannakou, C. K., Swain, F., Neeson, P., Steiner, T. M., Saghebi, J., Blombery, P., Hunter, S. M., …, & Dickinson, M. J. (2025). Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00481
Vancouver
Minson A, Verner E, Giri P, Butler J, Janowski W, Cheah CY, et al. Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-00481
BibTeX
@article{Minson2025,
author = {Minson, Adrian and Verner, Emma and Giri, Pratyush and Butler, Jason and Janowski, Wojt and Cheah, Chan Y and Ratnasingam, Sumita and Wong, Shu Min and Ku, Matthew and Hertzberg, Mark and Herbert, Kirsten and Hamad, Nada and Yannakou, Costas K and Swain, Fiona and Neeson, Paul and Steiner, Thiago M and Saghebi, Javad and Blombery, Piers and Hunter, Sally M and Robertson, Molly and Lau, Lei Shong and Bennett, Rory and Harrop, Sean and Xie, Jing and Seymour, John F and Dickinson, Michael J},
title = {Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-25-00481}
}
EUVIMED